Patents by Inventor Sunghoon Ma

Sunghoon Ma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190251696
    Abstract: A method and device that estimate a pose of a device and the device are disclosed. The method may include generating inertial measurement unit (IMU) data of the device, determining a first pose of the device a first time point based on the IMU data, generating a current predicted motion state array based on the IMU data, and estimating an M-th predicted pose of the device at an M-th time point after the first time point based on the current predicted motion state array, where M denotes a natural number greater than 1.
    Type: Application
    Filed: August 28, 2018
    Publication date: August 15, 2019
    Applicant: Samsung Electronics Co., Ltd.
    Inventors: Guangwei WANG, Tianhao GAO, Chun WANG, GeeYoung SUNG, Hong-Seok LEE, Lin MA, Minsu AHN, Qiang WANG, Sunghoon HONG, Yun-Tae KIM, Zhihua LIU
  • Patent number: 10035790
    Abstract: Described are RORy modulators of the formula (I), and N-oxides thereof, and pharmaceutically acceptable salts thereof, and solvates and hydrates thereof, wherein R1, R2, R3, R4, R5, R6, Ra, x, y, L, G, Z, the bond denoted by “q”, the ring system denoted by “A” and the ring system denoted by “B” are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORy activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORy activity, for example, autoimmune and/or inflammatory disorders.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: July 31, 2018
    Assignees: Exelixis, Inc., Bristol-Myers Squibb Co.
    Inventors: Wei Xu, Yong Wang, Sunghoon Ma, Elena S. Koltun, Byung Gyu Kim, Joon Won Jeong, T. G. Murali Dhar, Lynne Canne Bannen
  • Publication number: 20150266856
    Abstract: Described are RORy modulators of the formula (I), and N-oxides thereof, and pharmaceutically acceptable salts thereof, and solvates and hydrates thereof, wherein R1, R2, R3, R4, R5, R6, Ra, x, y, L, G, Z, the bond denoted by “q”, the ring system denoted by “A” and the ring system denoted by “B” are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORy activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORy activity, for example, autoimmune and/or inflammatory disorders.
    Type: Application
    Filed: October 17, 2013
    Publication date: September 24, 2015
    Inventors: Wei Xu, Yong Wang, Sunghoon Ma, Elena S. Koltun, Byung Gyu Kim, Joon Won Jeong, T.G. Muralii Dhar, Lynn Canne Bannen
  • Patent number: 8710038
    Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention.
    Type: Grant
    Filed: September 15, 2005
    Date of Patent: April 29, 2014
    Assignee: Exelixis, Inc.
    Inventors: Tae-Gon Baik, Chris A. Buhr, Sunghoon Ma, John M. Nuss, Zerom Tesfai, Longcheng Wang, Bryan K. S. Yeung
  • Patent number: 8648066
    Abstract: The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: February 11, 2014
    Assignee: Exelixis, Inc.
    Inventors: Neel Kumar Anand, Charles M. Blazey, Owen Joseph Bowles, Chris Allen Buhr, Joerg Bussenius, Jeffry Kimo Curtis, Steven Charles DeFina, Larisa Dubenko, Jason R. Harris, Eileen E. Jackson-Ugueto, Anagha Joshi, Angie Inyoung Kim, Amy Lew Tsuhako, Sunghoon Ma, Jean-Claire Limun Manalo, Stephanie Ng, Csaba J. Peto, Kenneth D. Rice, Tsze H. Tsang, Cristiana A. Zaharia
  • Patent number: 8247408
    Abstract: The invention is directed to Compounds of Formula I and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
    Type: Grant
    Filed: October 9, 2006
    Date of Patent: August 21, 2012
    Assignee: Exelixis, Inc.
    Inventors: Tae-Gon Baik, Chris A. Buhr, Katherine Lara, Sunghoon Ma, Longcheng Wang, Bryan K. S. Yeung
  • Patent number: 8101622
    Abstract: The invention is directed to Compounds of Formula I: optionally as a single stereoisomer or mixture of stereoisomers thereof, and additionally optionally as a pharmaceutically acceptable salt thereof; as well as methods of making and using the compounds.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: January 24, 2012
    Assignee: Exelixis, Inc.
    Inventors: Tae-Gon Baik, Sunghoon Ma, Chris A. Buhr, John M. Nuss
  • Patent number: 8044062
    Abstract: The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
    Type: Grant
    Filed: October 9, 2006
    Date of Patent: October 25, 2011
    Assignee: Exelixis, Inc.
    Inventors: Tae-Gon Baik, Chris A. Buhr, Katherine Lara, Sunghoon Ma, Morrison Mac, John M. Nuss, Longcheng Wang, Yong Wang, Bryan K. S. Yeung
  • Publication number: 20110237608
    Abstract: The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
    Type: Application
    Filed: June 2, 2011
    Publication date: September 29, 2011
    Applicant: Exelixis, Inc.
    Inventors: Tae-Gon Baik, Chris A. Buhr, Katherine Lara, Sunghoon Ma, Morrison Mac, John M. Nuss, Longcheng Wang, Yong Wang, Bryan K.S. Yeung
  • Patent number: 8012956
    Abstract: A compound according to Formula I or II: wherein R1, R1b, R2, L1, and L2 and L2b are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: September 6, 2011
    Assignee: Exelixis, Inc.
    Inventors: Kenneth D. Rice, Naing Aay, Neel Kumar Anand, Arlyn Arcalas, Tae-Gon Baik, Charles M. Blazey, Owen Joseph Bowles, Chris A. Buhr, Joerg Bussenius, Simona Costanzo, Jeffrey Kimo Curtis, Steven Charles Defina, Larisa Dubenko, Abigail R. Kennedy, Angie Inyoung Kim, Katherine Lara, Sunghoon Ma, Jean-Claire Limun Manalo, Csaba J. Peto, Tsze H. Tsang, Longcheng Wang
  • Publication number: 20100305093
    Abstract: The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
    Type: Application
    Filed: April 8, 2010
    Publication date: December 2, 2010
    Applicant: EXELIXIS, INC.
    Inventors: Neel Kumar Anand, Arlyn Arcalas, Charles M. Blazey, Chris A. Buhr, Jonah Cannoy, Sergey Ephsteyn, Henry William Beecroft Johnson, Anagha Joshi, Byung Gyu Kim, James W. Leahy, Matthew Sangyup Lee, Sunghoon Ma, Morrison B. Mac, John M. Nuss, Craig Stacy Takeuchi, Longcheng Wang, Yong Wang
  • Publication number: 20100298290
    Abstract: The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
    Type: Application
    Filed: May 20, 2010
    Publication date: November 25, 2010
    Applicant: EXELIXIS, INC.
    Inventors: Neel Kumar Anand, Charles M. Blazey, Owen Joseph Bowles, Chris Allen Buhr, Joerg Bussenius, Jeffry Kimo Curtis, Steven Charles DeFina, Larisa Dubenko, Jason R. Harris, Eileen E. Jackson-Ugueto, Anagha Joshi, Angie Inyoung Kim, Amy Lew Tsuhako, Sunghoon Ma, Jean-Claire Limun Manalo, Stephanie Ng, Csaba J. Peto, Kenneth D. Rice, Tsze H. Tsang, Cristiana A. Zaharia
  • Publication number: 20100150827
    Abstract: The invention is directed to a Compound of Formula I, II, or III. The invention provides compounds that inhibit, regulate, and/or modulate PI3K that are useful in the treatment of hyperproliferatives diseases, such as cancer.
    Type: Application
    Filed: April 11, 2008
    Publication date: June 17, 2010
    Applicant: Exelixis, Inc
    Inventors: Chris A. Buhr, William Bajjalieh, Anagha Abhijit Joshi, Katherine Lara, Sunghoon Ma, Charles K. Marlowe, Longcheng Wang, Bryan K.S. Yeung
  • Patent number: 7704995
    Abstract: This invention relates to compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and to pharmaceutical compositions containing such compounds. Even more specifically, the invention relates to compounds that inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Methods of therapeutically or prophylactically using the compounds and compositions to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer, as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amounts of such compounds.
    Type: Grant
    Filed: May 2, 2003
    Date of Patent: April 27, 2010
    Assignee: Exelixis, Inc.
    Inventors: Chris A. Buhr, Tae-Gon Baik, Sunghoon Ma, Zerom Tesfai, Longcheng Wang, Erick Wang Co, Sergey Epshteyn, Abigail R Kennedy, Baili Chen, Larisa Dubenko, Neel Kumar Anand, Tsze H. Tsang, John M. Nuss, Csaba J Peto, Kenneth D. Rice, Mohamed Abdulkader Ibrahim, Kevin Luke Schnepp, Xian Shi, James William Leahy, Jeff Chen, Lisa Esther Dalrymple, Timothy Patrick Forsyth, Tai Phat Huynh, Grace Mann, Larry Wayne Mann, Craig Stacy Takeuchi, Peter Lamb, David J. Matthews, Nicole Miller
  • Publication number: 20100087456
    Abstract: The invention is directed to Compounds of Formula I: optionally as a single stereoisomer or mixture of stereoisomers thereof, and additionally optionally as a pharmaceutically acceptable salt thereof; as well as methods of making and using the compounds.
    Type: Application
    Filed: September 29, 2009
    Publication date: April 8, 2010
    Applicant: Exelixis, Inc.
    Inventors: Tae-Gon Baik, Sunghoon Ma, Chris A. Buhr, John M. Nuss
  • Publication number: 20090270430
    Abstract: The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
    Type: Application
    Filed: October 9, 2006
    Publication date: October 29, 2009
    Applicant: Exelixix, Inc.
    Inventors: Tae-Gon Baik, Chris A. Buhr, Katherine Lara, Sunghoon Ma, Morrison Mac, John M. Nuss, Longcheng Wang, Yong Wang, Bryan K.S. Yeung
  • Publication number: 20090203577
    Abstract: The present invention relates to compounds of formula I, which exhibit affinity for the farnesoid X receptor.
    Type: Application
    Filed: December 12, 2006
    Publication date: August 13, 2009
    Applicant: EXELIXIS, INC.
    Inventors: Tae-Gon Baik, Chris A. Buhr, Brett B. Busch, Diva Sze-Ming Chan, Brenton T. Flatt, Xiao-Hui Gu, Vasu Jammalamadaka, Richard George Khoury, Katherine Lara, Sunghoon Ma, Richard Martin, Raju Mohan, John M. Nuss, Jason Jevious Parks, Jason H. Wu, Bryan K. S. Yeung, Wei Xu, Tie-Lin Wang, Longcheng Wang
  • Publication number: 20090163471
    Abstract: A compound according to Formula I or II: wherein R1, R1b, R2, L1, and L2 and L2b are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: October 27, 2008
    Publication date: June 25, 2009
    Inventors: Kenneth D. Rice, Naing Aay, Neel Kumar Anand, Arlyn Arcalas, Tae-Gon Baik, Charles M. Blazey, Owen Joseph Bowles, Chris A. Buhr, Joerg Bussenius, Simona Costanzo, Jeffrey Kimo Curtis, Steven Charles Defina, Larisa Dubenko, Abigail R. Kennedy, Angie Inyoung Kim, Katherine Lara, Sunghoon Ma, Jean-Claire Limun Manalo, Csaba J. Peto, Tsze H. Tsang, Longcheng Wang
  • Publication number: 20090062274
    Abstract: The invention is directed to Compounds of Formula I and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
    Type: Application
    Filed: October 9, 2006
    Publication date: March 5, 2009
    Applicant: Exelixis, Inc
    Inventors: Tae-Gon Baik, Chris A. Buhr, Katherine Lara, Sunghoon Ma, Longcheng Wang, Bryan K.S. Yeung
  • Publication number: 20070293507
    Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention.
    Type: Application
    Filed: September 15, 2005
    Publication date: December 20, 2007
    Applicant: EXELIXIS, INC.
    Inventors: Tae-Gon Baik, Chris Buhr, Sunghoon Ma, John Nuss, Zerom Tesfai, Longcheng Wang, Bryan Yeung